Ursula Matulonis, MD, on Concordance of CA-125 and Radiographic Progression in Ovarian Cancer
February 21, 2024 9:00 amBy Mark Fuerst
About half of patients with platinum-sensitive relapsed ovarian cancer (PSROC) on maintenance poly (ADP-ribose) polymerase inhibitor (PARPi) therapy who showed RECIST progression did not have cancer antigen-125 (CA-125) progression, challenging current guidelines, according to a new study.… Read more